Study: Psychedelics Disrupt Brain-Immune Signals That Promote Fear
Could the benefits of psychedelics go beyond the brain and impact the immune system? New research suggests an unexpected potential advantage of psychedelics is emerging.
Fear and the immune system could be connected in unexpected ways. Researchers at Mass General Brigham, in affiliation with Harvard Medical School, found that the immune system influences stress and fear behaviors by altering how brain cells communicate. Using preclinical models and human tissue samples, they also found that psychedelics could target these neuroimmune interactions, disrupting them to reduce stress-induced fear. The findings were published April 23 in Nature.
The amygdala, known as the brain's fear center, processes threats. Some fears—like the fight-or-flight response—are essential for survival. Others pile up and become overwhelming. Researchers believe psychedelics such as MDMA and psilocybin may interrupt unhelpful neuroimmune signals when anxiety, depression, and conditions occur.
Michael Wheeler, a founding member of the Mass General Brigham health care system, is based at the Gene Lay Institute of Immunology and Inflammation and the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital in Boston.
'Our research shows that psychedelics don't just have powerful effects on the brain's ability to adapt and change, they also seem to rebalance the way the brain interacts with the body,' Wheeler said in an exclusive statement. 'We found that by limiting the brain's exposure to fear-promoting signals from nearby immune cells, psychedelics might help keep the immune system in check, offering unexpected benefits beyond cognitive effects.'
The study provides insight into the mechanisms at play when psychedelics interact with both the brain and the body, shedding light on their expanding potential in therapeutic settings.
Research in the past has shown immune signals can promote the development of neuropsychiatric conditions such as major depressive disorder (MDD). Looking ahead, psychedelics may provide useful tools in controlling these signals.
In experiments with mouse models under chronic stress, researchers observed increased signaling in the amygdala that amplified fear behaviors, triggered inflammatory responses, and activated fear-promoting neurons. They also found that during chronic stress, inflammatory immune cells called monocytes migrated from other parts of the body to the brain. When stressed mice were given psilocybin and MDMA, monocyte accumulation in the brain was reduced, and fear behaviors decreased.
'We're especially excited to keep exploring how the immune system factors into psychedelic therapy, both in humans and in mice, and to see whether psychedelics could also have potential as treatments for other inflammatory diseases,' Wheeler wrote.
They also found similar signals in human brain cells and in gene expression datasets from patients with MDD, suggesting that the same interactions between the immune system and the brain may pave the way for treatments for neuropsychiatric disorders.
Wheeler is also collaborating with Massachusetts General Hospital Center for the Neuroscience of Psychedelics on a clinical trial of people with depression who are being treated with psychedelic, examining their tissue samples.
Wheeler and colleagues expressed interest in further examining the effects of psychedelics on people with depression and inflammatory diseases. Mass General Brigham, one of the nation's leading biomedical research organizations, operates across several Harvard Medical School hospitals.
Recent strides have been made in demonstrating the therapeutic effects of psychedelics like MDMA. The FDA initially acknowledged MDMA's therapeutic potential for PTSD, but ultimately rejected a new drug application, submitted by Lykos Therapeutics (formerly MAPS Public Benefit Corporation). Amid the psychedelic renaissance in medicine, research is leading to potential benefits from psilocybin for treatment-resistant depression, MDD, and addiction.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Tom's Guide
15 hours ago
- Tom's Guide
Trouble sleeping? 'Moon breathing' can reduce anxiety at night, says expert
Even when you've created the perfect environment for sleep and are exhausted from a busy day, sleep can be elusive if you experience nighttime anxiety — which can include trouble relaxing, night sweats, panic attacks and increased waking during the night. But what if we told you that an ancient yogic breathing technique could be a tool in your arsenal to challenge it? Moon breathing is a term that has become more popular more recently thanks to social media platforms like TikTok. This breathing technique is focused on using your left nostril, and can lead to a range of benefits, including activating the parasympathetic nervous system (the part of our autonomic nervous system associated with relaxation), lowering the heart rate and preparing the body and mind for sleep. To explore more about what moon breathing is, exactly why it can help with nighttime anxiety and sleep, and how you can try it, we've spoken to licensed clinical psychologist specializing in sleep and trauma, and yoga teacher, Dr. Leah Kaylor Ph.D. PLLC.. "Moon breathing is a calming yogic breathwork technique rooted in ancient Indian practices of pranayama. In yogic philosophy, the left nostril is associated with lunar (moon) energy—cool, calm, and introspective," says Dr. Kaylor. It's a breathing exercise that involves inhaling slowly through your left nostril only, while keeping the right nostril closed, then exhaling through the right nostril while closing the left. A paper published in Nature exploring the changes in brain activity recorded by EEG during nasal breathing noted that, "Yogic practices suggest, and scientific evidence demonstrates, that right-nostril breathing is involved with relatively higher sympathetic activity (arousal states), while left-nostril breathing is associated with a relatively more parasympathetic activity (stress alleviating state)." "By breathing exclusively through the left nostril, this technique is thought to activate the parasympathetic nervous system, promoting relaxation and emotional ease," explains Dr. Kaylor. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. The sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS) are both part of our autonomic nervous system, with research noting that the former is connected to our alert, "fight or flight," response and the latter with "rest and digest" processes, when we are in a relaxed state. "Moon breathing works by channeling breath solely through the left nostril, which is believed to stimulate the brain's right hemisphere — the part associated with calmness, intuition, and emotional regulation," says Dr. Kaylor. The benefits of this, she says, can include reducing sympathetic (stress) arousal, activating the parasympathetic nervous system and lowering heart rate and blood pressure. Plus, moon breathing can help promote mental stillness and emotional grounding, and prepare our bodies for introspection, rest or sleep. One study looked at the effect of different yogic breathing techniques that utilise the left and right nostrils, and both, to see if they had differing effects on reaction time, heart rate and blood pressure. The researchers concluded from their results that moon breathing was among the left nostril techniques that "may induce a state of parasympathetic dominance as seen in (cardiovascular) parameters." They further noted that their findings are in line with "the traditional swara yoga concept that... the flow through left nostril (chandra nadi and ida swara) is relaxatory." Dr. Kaylor explains that moon breathing is particularly effective for pre-sleep anxiety because it: If you're experiencing regular nighttime anxiety, it's important to consult a medical professional for advice. If you want to incorporate moon breathing into your nighttime routine as a tool to combat it, Dr. Kaylor has some simple steps you can follow. The 4-7-8 method is a breathing technique that gained popularity after Dr. Andrew Weil began teaching it, and involves breathing in through your nose for a count of four, holding that breath for a count of seven, and then slowly breathing out through your mouth for a count of eight. Dr. Kaylor explains that the main difference between these two breathing techniques is that "moon breathing is through one nostril." "Moon breathing is best for highly anxious or overstimulated individuals," she says, explaining that it is "ideal for those experiencing hyperarousal or sympathetic overdrive (e.g., anxiety, racing thoughts, agitation)." Because moon breathing does not involve holding your breath, it can also be good breathing technique for those who are sensitive to breath retention, she says, or, those who find it distressing or physiologically uncomfortable. That could include people with a panic disorder or asthma. "4-7-8 is best suited for people with experience in controlled breathing or mindfulness," says Dr. Kaylor. "The extended breath-hold can feel challenging for beginners or those with respiratory sensitivity," she adds, noting that it can suit others too, including those who benefit from structure and counting, and those with sleep-onset insomnia. This is because "studies and anecdotal evidence suggest that 4-7-8 is particularly effective at quieting the mind and inducing a sleep-conducive state." Stress and anxiety are typically associated with higher levels of cortisol, which can increase heart rate and blood pressure. Cortisol is also the sleep hormone associated with making us feel awake and alert, which means that when it's increased, sleep will be more difficult. However, a review of studies looking at the effects of breathing exercises found "that breathing exercises have positive effect on decreasing the blood pressure and heart rate." Dr. Kaylor says, deep breathing can also help to "release physical tension in the body, particularly in the shoulders, chest, and jaw." And, in giving our brains something simple and rhythmic to focus on, deep breathing techniques can "interrupt cognitive rumination." Deep breathing has even been shown to increase melatonin production, the hormone our bodies produce in the evening and which helps us to feel sleepy. One study found that a group of 15 participants who practiced deep breathing alongside meditation and yogic postures for a period of three months saw an increase in plasma melatonin (which is the concentration of melatonin in our blood). In addition, Dr. Kaylor explains that deep breathing can "reduce cortisol levels, allowing melatonin to rise naturally." As well as helping you drift off in a calmer state, it can also help your overall sleep. Research showed that when a group of students practiced moon breathing for four weeks it 'led to improvement in sleep quality." Deep breathing is an incredibly affective way of activating our parasympathetic nervous system, creating a sense of calm and relaxation needed for sleep. Slower, deeper breaths into your diaphragm, "increases the pressure of oxygen in the air sacs, making it easier for oxygen molecules to move into the blood via the capillaries," neuroscience researcher Dr. Yewande Pearce explains in this useful Headspace video.
Yahoo
a day ago
- Yahoo
Psychedelics as potential mental health treatment are explored by Trump administration
The Trump administration has expressed interest in exploring psychedelics for their potential in treating PTSD and other debilitating mental health issues, various officials have shared. "The Department shares the goal of ensuring that all Americans — especially our nation's veterans — have access to safe and effective treatments for conditions such as PTSD, addiction and depression," a spokesperson for the U.S. Department of Health and Human Services (HHS), run by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital. "Secretary Kennedy is committed to applying rigorous, evidence-based science to research efforts aimed at addressing these serious health challenges." Fda Approves First Ai Tool To Predict Breast Cancer Risk In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin ("magic mushrooms") to treat mental health disorders. MDMA is not approved for clinical use by the U.S. Food and Drug Administration (FDA), but can be studied in clinical settings. Read On The Fox News App Psilocybin is listed as a Schedule I substance under the Controlled Substances Act, which means it has "a high potential for abuse, [is not] currently accepted for medical use in treatment in the United States, and [has] a lack of accepted safety for use under medical supervision." Psilocybin-assisted therapy, however, is legal in Oregon, Colorado and New Mexico. Psychedelic medicines are "showing real promise," according to Dr. Luke Twelves, general practitioner and vice president of medical for Lindus Health in London. Clinical trials have found such treatments safe and effective for patients battling serious mental health issues, according to Twelves. Common Supplements And Medications Could Cause Liver Damage, Studies Show "Take psilocybin, for example — it's demonstrating remarkable results for severe depression that hasn't responded to other medications," he told Fox News Digital. "MDMA is showing similar breakthroughs for PTSD treatment." Clinical trials are also investigating how psychedelics could help with end-of-life anxiety, addiction, eating disorders, chronic pain and OCD, he added. Researchers have faced challenges in terms of regulatory hurdles and proper placebo controls, Twelves said. "Given that these treatments could transform [the] lives of people suffering from conditions where nothing else has worked effectively, it's crucial that we complete this research properly," he said. "The goal is to bring safe, proven psychedelic therapies to the patients who need them most." At President Trump's May 1 cabinet meeting, Department of Veterans Affairs Secretary Doug Collins said that "we're opening up the possibility of psychedelic treatment." Retired Army Sergeant Jonathan Lubecki recently told Fox News' Alexandria Hoff that MDMA stopped his PTSD while he was participating in a clinical trial. "[I] took my first dose of MDMA. I've only taken it three times as part of the clinical trial, haven't taken it since, and haven't found the need to take it since, because I haven't had PTSD," he said. Peter Kasperowicz, Department of Veterans Affairs press secretary, told Fox News Digital the department is safely exploring all avenues that promote the health of veterans. Fallujah Vet Turns Medal Of Heroism Into A Healing Mission For Fellow Warriors With Service Dogs Program "Preliminary findings have produced positive results on psychedelic-assisted therapies for treating mental health conditions," he said. The VA is currently running 11 clinical trials in various phases, with a total of some 800 veterans expected to participate. "The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depressive disorder, major depressive disorder and potentially other mental health conditions," said Kasperowicz. An MDMA study published in the Jan. 2025 issue of The American Journal of Psychiatry found that the substance is "unlike classical psychedelics." The study noted, "MDMA allows the individual to maintain intact ego functioning and a greater degree of cognitive and perceptual lucidity while still experiencing a prosocial altered state of consciousness that facilitates deeply emotional therapeutic breakthroughs." Click Here To Sign Up For Our Health Newsletter The researchers concluded that MDMA showed "enhanced levels of trust, empathy, self-compassion and a 'window of tolerance'" that traditional psychotherapy lacks. Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that "the time is now to address the mental health crisis." He said it is "gratifying" that administration officials value the potential benefits of looking into alternative mental health treatments. Cybin is currently in phase 3 of a study of CYB003, a type of psilocybin that has been granted breakthrough therapy designation by the FDA as an additional treatment for major depressive disorder (MDD). "In Cybin's completed Phase 2 MDD study, long-term efficacy results showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003," said Drysdale. Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News' senior medical analyst, previously interviewed two of the country's top researchers on psychedelics — Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone. "They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses," Siegel told Fox News Digital at the time. "Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts," Siegel added. Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, emphasized it's important to administer psychedelics in a safe setting when treating mental health conditions. For more Health articles, visit "Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials." To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed article source: Psychedelics as potential mental health treatment are explored by Trump administration
Forbes
2 days ago
- Forbes
Why The ‘Strawberry Moon' Will Be Lowest Until 2043 — And How To Photograph It
Tuesday's full strawberry moon occurs during two-year period known as the 'major lunar standstill" ... More or "lunistice," when a once-in 18.6-year event will create the lowest-hanging full moon since 2006 and until 2043. The full moon is seen here rising behind Stonehenge in England. (Photo by) The full strawberry moon will put on a dramatic show at moonrise on Tuesday, June 10 — low, luminous, and colored orange as it climbs into the southeastern sky. Get to an observing location that looks southeast — preferably low to the horizon — and at the specific time of moonrise where you are (during dusk), you'll see the red-orange orb rise before your eyes. Seen from the Northern Hemisphere, the full moon will rise far to the southeast, move across the sky close to the southern horizon, and set in the southwest close to dawn. It's happening because we're in the midst of a rare two-year period known as the 'major lunar standstill" or "lunistice," when a once-in 18.6-year event will create the lowest-hanging full moon since 2006 and until 2043. Earth's axis is tilted by 23.5 degrees with respect to the ecliptic, the path of the sun through the daytime sky, and, in effect, the plane of the solar system. That's what gives us seasons, and that's why planets are always found close to the ecliptic (hence the misused "planetary alignment" claims despite planets always being somewhat aligned with each other). The moon's orbit crosses the ecliptic twice each month, and when those crossings align with a new or full moon, eclipses can occur — hence the shared root in the words 'ecliptic' and 'eclipse.' While the sun's rise and set points vary throughout the year, changing by 47 degrees — and reaching the extreme points at the solstices — the moon's range is bigger, with that 5-degree tilt giving its rise and set points a 70-degree range near a major standstill, according to Griffith Observatory. Mount Coot-tha Lookout, Brisbane A major lunar standstill is a period when the northernmost and southernmost moonrise and moonset are furthest apart. Unlike a solstice (Latin for "sun stand still"), which lasts for one day, a major lunar standstill lasts for two years. These events are most noticeable during a full moon. Essentially, the swiveling and shifting orbit of the moon — a consequence of the sun's gravitational pull — is tilted at its maximum angle relative to the ecliptic. Every 18.6 years, the tilts combine to cause the moon to rise and set as much as 28.5° north or south of due east and west, respectively. Most people won't notice the major lunar standstill, but if you regularly watch the full moon rise from a particular place, go there — you'll get a shock when the moon rises at an extreme position much farther from where you might imagine it will rise. Imaging a full moon using a smartphone isn't easy, but it is possible to capture something special. First, switch off your flash and turn on HDR mode (if available) to better capture both the moon and the landscape as the light fades during dusk. Don't zoom in because digital zoom only blurs the details. Instead, frame the moon within a landscape for more impact, which is especially effective during this month's unusually far-southeast moonrise. If you use a manual photography app, stick to an ISO of 100 for a clean shot and experiment with slower (but not too slow) shutter speeds. A tripod will help, especially when using slow shutter speeds. However, if you don't have one, you can balance your phone on a wall or ledge. The key is to image it when it's low on the horizon and glowing orange. You've got a short window to capture that color, even with this low-hanging full moon, which will turn bright white as it lifts above the horizon. Wishing you clear skies and wide eyes.
